10.92  3.28 (42.93%)		01-13 16:00
Open: 11.96 High: 12.1 Volume: 7,324,205		Pre. Close: 7.64 Low: 9.0616 Market Cap: 21(M)

Short term
Mid term
Targets	6-month :	15.28	1-year :	17.85
Resists	First :	13.09	Second :	15.28
Pivot price	7.8
Supports	First :	9.04	Second :	6.55
MAs	MA(5) :	8.04	MA(20) :	8.07
	MA(100) :	9.77	MA(250) :	21.91
MACD	MACD :	-0.4	Signal :	-0.7
%K %D	K(14,3) :	45	D(3) :	30.8
RSI	RSI(14): 63.3
52-week	High :	98.19	Low :	3.5

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BCTX ] has closed Bollinger Bands are 2.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	12.12 - 12.16	12.16 - 12.21
Low:	8.97 - 9.01	9.01 - 9.05
Close:	10.84 - 10.92	10.92 - 10.99

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Wed, 14 Jan 2026
What's Going On With BriaCell Therapeutics Stock Wednesday? - Benzinga

Wed, 14 Jan 2026
BriaCell Therapeutics (BCTX) Launches $30M Public Offering - GuruFocus

Tue, 13 Jan 2026
BriaCell Therapeutics Announces Pricing of $30 million Public Offering - Yahoo Finance Singapore

Tue, 13 Jan 2026
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS Patient - Finviz

Tue, 13 Jan 2026
Price Target Adjustments Send BCTX Stock Tumbling - timothysykes.com

Tue, 13 Jan 2026
78-year-old breast cancer patient sees lung tumor vanish for 11 months - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	2 (M)
Shares Float	2 (M)
Held by Insiders	2.3 (%)
Held by Institutions	4.1 (%)
Shares Short	102 (K)
Shares Short P.Month	115 (K)

EPS	-33.87
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.3
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-161.7 %
Return on Equity (ttm)	-444.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-16.11
Qtrly Earnings Growth	0 %
Operating Cash Flow	-29 (M)
Levered Free Cash Flow	-19 (M)

PE Ratio	-0.33
PEG Ratio	0
Price to Book value	2.06
Price to Sales	0
Price to Cash Flow	-0.71

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.